Altimmune (NASDAQ:ALT) Stock Price Up 4.9% – Should You Buy?

Altimmune, Inc. (NASDAQ:ALT)’s share price shot up 4.9% during trading on Friday . The company traded as high as $9.02 and last traded at $9.01. 1,826,223 shares changed hands during trading, a decline of 52% from the average session volume of 3,833,614 shares. The stock had previously closed at $8.59.

Wall Street Analyst Weigh In

ALT has been the subject of a number of recent analyst reports. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday, November 14th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Altimmune has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Trading Up 4.2 %

The firm has a 50-day moving average of $7.65 and a two-hundred day moving average of $7.05. The firm has a market capitalization of $636.57 million, a P/E ratio of -5.55 and a beta of 0.15.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the business posted ($0.39) earnings per share. On average, sell-side analysts anticipate that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Altimmune

A number of institutional investors and hedge funds have recently bought and sold shares of ALT. Price T Rowe Associates Inc. MD grew its holdings in shares of Altimmune by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock worth $156,000 after purchasing an additional 1,821 shares during the last quarter. California State Teachers Retirement System increased its position in Altimmune by 517.7% in the 1st quarter. California State Teachers Retirement System now owns 53,730 shares of the company’s stock valued at $547,000 after acquiring an additional 45,032 shares during the period. SG Americas Securities LLC raised its stake in shares of Altimmune by 542.8% during the second quarter. SG Americas Securities LLC now owns 254,571 shares of the company’s stock valued at $1,693,000 after acquiring an additional 214,968 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in shares of Altimmune during the second quarter valued at $860,000. Finally, Horizon Wealth Management LLC acquired a new position in shares of Altimmune during the second quarter worth $66,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.